CN105832675B - 一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 - Google Patents
一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 Download PDFInfo
- Publication number
- CN105832675B CN105832675B CN201610176687.3A CN201610176687A CN105832675B CN 105832675 B CN105832675 B CN 105832675B CN 201610176687 A CN201610176687 A CN 201610176687A CN 105832675 B CN105832675 B CN 105832675B
- Authority
- CN
- China
- Prior art keywords
- selenium
- chitosan
- preparation
- chitosan microball
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 121
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 120
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 97
- 239000011806 microball Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- -1 selenium anion Chemical class 0.000 title claims abstract description 23
- 238000013268 sustained release Methods 0.000 title claims abstract description 19
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 19
- 239000012071 phase Substances 0.000 claims abstract description 48
- 239000000758 substrate Substances 0.000 claims abstract description 25
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims abstract description 14
- 239000011781 sodium selenite Substances 0.000 claims abstract description 13
- 239000008346 aqueous phase Substances 0.000 claims abstract description 10
- 229910003424 Na2SeO3 Inorganic materials 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910018143 SeO3 Inorganic materials 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 239000003208 petroleum Substances 0.000 claims abstract description 7
- 239000013049 sediment Substances 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000004132 cross linking Methods 0.000 claims description 12
- 238000013019 agitation Methods 0.000 claims description 11
- 239000005662 Paraffin oil Substances 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004945 emulsification Methods 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000007711 solidification Methods 0.000 claims description 6
- 230000008023 solidification Effects 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 2
- 238000005352 clarification Methods 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 18
- 238000005538 encapsulation Methods 0.000 abstract description 6
- 238000013517 stratification Methods 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 238000011300 routine therapy Methods 0.000 abstract description 3
- 238000002626 targeted therapy Methods 0.000 abstract description 3
- 239000011805 ball Substances 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 229940091258 selenium supplement Drugs 0.000 description 80
- 239000000463 material Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 4
- 229960001471 sodium selenite Drugs 0.000 description 4
- 235000015921 sodium selenite Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011807 nanoball Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法,取Na2SeO3于醋酸溶液中,配制成硒醋酸溶液;再加入壳聚糖,配制成水相基质;量取Span‑80于液体石蜡中配制成油相基质;将水相基质缓慢滴加到油相基质中搅拌,再缓慢滴加交联剂,继续搅拌,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤直至滤液澄清透明,滴加丙酮,于45℃烘箱中烘干即得。载硒壳聚糖微球呈球性能良好,包封率在27.54%‑75.82%范围,载药量在1.45%‑9.01%范围内,载硒壳聚糖微球粒径在50‑600μm之间,有效缓释时间可达116天,可控补硒量。本发明为抗癌药物SeO3 2‑离子构建一个缓释系统,通过模型药物缓释硒,拓宽给药方式,可用于常规或靶向疗法,提高药物生物利用度。
Description
技术领域
本发明涉及生命科学、医疗靶向材料的天然高分子缓释微球制造领域,具体是一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法。
背景技术
近代研究已证实人体必须营养微量元素硒具有抗氧化、抗肿瘤、抗炎症、抗高血压、降血糖、提高免疫力等广泛的生物学功能和药理作用,特别是其防癌抗癌功能。人体缺硒易导致免疫能力下降,威胁人类健康和生命的四十多种疾病都与缺硒相关。在硒元素的几种存在形态中,无机亚硒酸负离子的活性生理功能尤为突出:作为药物片剂,临床上用于治疗和防治癌症、早衰、高血压、心血管疾病、更年期症状、皮肤病、性功能障碍、克山病、大骨节病等疾病,与抗癌药物(如氟尿嘧啶)联合用药疗效增强,作为化疗辅助药物可以减轻患者的痛苦。细胞实验证实亚硒酸负离子能显著诱导鼻咽癌、结直肠癌、肝肺癌、乳腺胰腺癌等癌细胞的凋亡。但硒元素和人体其他生命元素一样是把双刃剑,缺少引发多种疾病,适量有益,超量反而引起机体中毒。一切硒产品如若短时间内硒释放量过大,反而有害身体。因此,无机亚硒酸负离子药物虽治病、抗癌等效力强但用量难以把握,临床上易过量而造成中毒,使得其广泛应用受到极大限制。怎样让硒产品材料能长时间缓慢释放安全有效的硒作用浓度将是影响其应用的瓶颈因素。
壳聚糖(chitosan,CS)是唯一一种天然聚阳离子弱碱性多糖,除具有体内止血、抑菌等生理活性外,其无毒性、良好的生物相容性和可降解性,被誉为最具应用前景的载药材料之一。国内外研究将壳聚糖制备成微/纳米球等靶向给药缓释材料,在药物运送、缓释、控释等方面发挥重要作用。根据反应介质和体系特性,目前壳聚糖微球的制备方法主要有乳化交联法、离子凝胶法、喷雾干燥法、凝聚/沉淀法、溶剂蒸发法等。其中乳化交联法可包载亲水或疏水的多物种,且具有微球结构较为致密,球形较规整,粒径小、分散性好、载药量较为理想等优点,可用于普通药物(如法莫替丁、奈普生、甲硝唑、引哚美辛、阿司匹林、布洛芬等)的载体,生物大分子药物(如疫苗、蛋白质、多肽)载体、抗癌药物(如丝裂霉素、顺铂、紫杉醇、喜树碱等)的载体,实验证明微/纳米球能提高药物稳定性,将药物缓慢释放并靶向送达体内的作用部位,保持药物长期活性,保护药物免受消化道酶的破坏及pH值的影响。作为营养药物(目前只有维生素)载体的研究报道相对较少。壳聚糖微球的制备工艺参数的优化和应用是未来药缓释功能材料研究的重要方向。而壳聚糖载硒缓释微球的研究国内外尚未见报道。
发明内容
本发明的目的在于提供一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法,制得的载硒壳聚糖微球的粒径范围为40-600μm,材料缓释硒可达116天,每天释硒量在57.58μg-0.606μg区间范围。
为实现上述目的,本发明提供如下技术方案:
一种可控缓释硒负离子的载硒壳聚糖微球的制备方法,包括以下步骤:
(1)水相基质的制备:称取Na2SeO3于2%(v/v)的醋酸溶液中,配制成硒醋酸溶液;称取壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成含硒壳聚糖溶液,静置过夜使其澄清透明,即为制备载硒壳聚糖微球所需的水相基质;
(2)油相基质的制备:量取Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系,此为制备载硒壳聚糖微球所需的油相基质;
(3)载硒壳聚糖微球的乳化、交联、固化及精制:在一定温度条件下,按水:油(v:v)=1:5将水相基质缓慢滴加到油相基质中,边滴加边磁力搅拌,待水相基质滴加完全后,继续搅拌1h,使水油两相充分乳化,缓慢滴加交联剂,继续搅拌2h,使交联剂与壳聚糖充分交联,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤直至滤液澄清透明,此即为载硒壳聚糖微球半成品;滴加丙酮,使载硒壳聚糖微球相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。
作为本发明进一步的方案:步骤(1)中,含硒壳聚糖溶液中壳聚糖质量浓度为0.5%-3%。
作为本发明进一步的方案:步骤(1)中,含硒壳聚糖溶液中壳聚糖质量浓度为1%-2%。
作为本发明进一步的方案:步骤(1)中,硒醋酸溶液中Na2SeO3的质量浓度为0.2%-1.6%。
作为本发明进一步的方案:步骤(1)中,硒醋酸溶液中Na2SeO3的质量浓度为0.4%-0.8%。
作为本发明进一步的方案:步骤(3)中,反应温度为35℃-65℃。
作为本发明进一步的方案:步骤(3)中,反应温度为45℃-55℃。
作为本发明进一步的方案:步骤(3)中,交联剂用量为2.5%-15%。
作为本发明进一步的方案:步骤(3)中,交联剂用量为5%-10%。
作为本发明进一步的方案:交联剂为质量分数为12.5%的戊二醛溶液。
本发明的另一目的是根据上述制备方法制得载硒壳聚糖微球。制备的载硒壳聚糖微球呈球性能良好,包封率在27.54%-75.82%范围,载药量在1.45%-9.01%范围内,载硒壳聚糖微球粒径在50-600μm之间,有效缓释时间可达116天。
与现有技术相比,本发明的有益效果是:
本发明创造的有益效果是:本发明以天然壳聚糖为壁材基质,采用乳化交联法在不同的条件下制备载硒负离子壳聚糖微球,以石蜡油为分散介质,Span-80为乳化剂,戊二醛为交联剂,以粒径分布和包封率为评价指标对制备工艺进行优化,将引入的药物封装在微球中,通过调控载药物量、微球的粒径和材质等方式,实现对材料缓释活性硒量的控制。
本发明可控补硒量。载硒壳聚糖微球,缓释安全的活性硒作用浓度,有效解决了一直以来补硒量难以把握的难题,可防止盲目补硒可能造成的急/慢性硒中毒现象,使硒的多种生理活性功能能够充分合理应用;涉及一种科学补硒的应用模式,作为某些需要长效释放硒药物的载体,给药方式可采用常规或靶向疗法,提高药物生物利用度;将硒和壳聚糖复合于一体的微球,兼具二者的活性功能,应用中可发挥二者的活性功效。
本发明结合壳聚糖和硒的优良特性,制备可控缓释硒的壳聚糖微球,为抗癌药物SeO3 2-离子构建一个缓释系统,通过模型药物缓释硒,避免SeO3 2-药物在体内的过量而引发的中毒难题,且拓宽给药方式,可用于常规或靶向疗法,使硒的多种生理活性功能能够充分合理应用,提高药物生物利用度。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本发明实施例中,不同的壳聚糖浓度制备载硒壳聚糖微球:(1)载硒壳聚糖基质水相的制备:准确称取一定质量亚硒酸钠于2%(v/v)的醋酸溶液中,配制含Na2SeO3为0.2%的硒醋酸溶液;称取一定量的壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成壳聚糖浓度为0.5%、1%、2%、3%的载硒壳聚糖溶液,静置过夜至澄清透明;(2)油相基质的制备:量取一定量的Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系;(3)载硒壳聚糖微球的乳化、交联、固化及精制:在35℃温度下,按水:油(v:v)=1:5将水相缓慢滴加到油相中,边滴加边磁力搅拌,待水相滴加完全后,继续搅拌1h,使水油两相充分乳化,缓慢滴加质量浓度为12.5%的戊二醛,使其量达到总体积的5%,搅拌交联2h,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤数次直至滤液澄清透明,此即为载硒壳聚糖微球。滴加数滴丙酮,使微球颗粒相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。当壳聚糖浓度为0.5%、1%、2%、3%的条件下,微球的包封率为37.61%、56.62%、68.11%、75.82%范围,载药量为3.27%、2.14%、1.92%、1.45%。
实施例2
本发明实施例中,不同的Na2SeO3浓度制备载硒壳聚糖微球:(1)载硒壳聚糖基质水相的制备:准确称取一定质量亚硒酸钠于2%(v/v)的醋酸溶液中,配制含Na2SeO3为0.2%、0.4%、0.8%、1.6%的硒醋酸溶液;称取一定量的壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成壳聚糖浓度为2%的载硒壳聚糖溶液,静置过夜至澄清透明;(2)油相基质的制备:量取一定量的Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系;(3)载硒壳聚糖微球的乳化、交联、固化及精制:在35℃温度下,按水:油(v:v)=1:5将水相缓慢滴加到油相中,边滴加边磁力搅拌,待水相滴加完全后,继续搅拌使水油两相乳化1h,缓慢滴加质量浓度为12.5%的戊二醛,使其量达到总体积的5%,搅拌交联2h,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤数次直至滤液澄清透明,此即为载硒壳聚糖微球。滴加数滴丙酮,使微球颗粒相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。当Na2SeO3浓度为0.2%、0.4%、0.8%、1.6%的条件下,微球的包封率为63.51%、56.72%、56.30%、27.54%,载药量为2.17%、3.42%、5.52%、9.01%。
实施例3
本发明实施例中,不同的反应温度制备载硒壳聚糖微球。(1)载硒壳聚糖基质水相的制备:准确称取一定质量亚硒酸钠于2%(v/v)的醋酸溶液中,配制含Na2SeO3为0.2%的硒醋酸溶液;称取一定量的壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成壳聚糖浓度为2%的载硒壳聚糖溶液,静置过夜至澄清透明;(2)油相基质的制备:量取一定量的Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系;(3)载硒壳聚糖微球的乳化、交联、固化及精制:在反应温度为35℃、45℃、55℃、65℃的条件下进行试验,按水:油(v:v)=1:5将水相缓慢滴加到油相中,边滴加边磁力搅拌,待水相滴加完全后,继续搅拌1h,使水油两相充分乳化,缓慢滴加质量浓度为12.5%的戊二醛,使其量达到总体积的5%,搅拌交联2h,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤数次直至滤液澄清透明,此即为载硒壳聚糖微球。滴加数滴丙酮,使微球颗粒相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。当反应温度为35℃、45℃、55℃、65℃的条件下,微球的包封率为62.30%、64.68%、69.26%、64.35%,载药量为2.09%、2.12%、2.08%、1.90%。
实施例4
本发明实施例中,不同的交联剂用量制备载硒壳聚糖微球:(1)载硒壳聚糖基质水相的制备:准确称取一定质量亚硒酸钠于2%(v/v)的醋酸溶液中,配制含Na2SeO3为0.2%的硒醋酸溶液;称取一定量的壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成壳聚糖浓度为2%的载硒壳聚糖溶液,静置过夜至澄清透明;(2)油相基质的制备:量取一定量的Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系;(3)载硒壳聚糖微球的乳化、交联、固化及精制:在35℃温度下,按水:油(v:v)=1:5将水相缓慢滴加到油相中,边滴加边磁力搅拌,待水相滴加完全后,继续搅拌1h,使水油两相充分乳化,缓慢滴加质量浓度为12.5%的戊二醛作为交联剂,且分别在交联剂的用量为2.5%、5%、10%、15%的条件下进行试验,搅拌交联2h,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤数次直至滤液澄清透明,此即为载硒壳聚糖微球。滴加数滴丙酮,使微球颗粒相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。当交联剂用量为2.5%、5%、10%、15%的条件下,微球的包封率为57.33%、67.31%、75.40%、54.92%,载药量为1.96%、2.40%、2.29%、1.70%。
上述实施例虽对本发明的设计思路作了详细的文字叙述,但这些文字描述只是对本发明设计思路的简单文字描述,而非对本发明设计思路的限制,任何不超出本发明设计思路的组合、增加或修改,比如其它高分子(如魔芋葡甘聚糖、聚乳酸等)载硒的载体,交联剂改为甲醛、焦磷酸等,油相或乳化剂作适当修改等等,均落入本发明的保护范围内。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
Claims (10)
1.一种可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,包括以下步骤:
(1)水相基质的制备:称取Na2SeO3于2%(v/v)的醋酸溶液中,配制成硒醋酸溶液;称取壳聚糖固体粉末于硒醋酸溶液中,磁力搅拌使壳聚糖完全溶解,配制成含硒壳聚糖溶液,静置过夜使其澄清透明,即为制备载硒壳聚糖微球所需的水相基质;
(2)油相基质的制备:量取Span-80于液体石蜡中,搅拌均匀,配制成含5%(v/v)Span-80的石蜡油体系,此为制备载硒壳聚糖微球所需的油相基质;
(3)载硒壳聚糖微球的乳化、交联、固化及精制:在一定温度条件下,按水:油(v:v)=1:5将水相基质缓慢滴加到油相基质中,边滴加边磁力搅拌,待水相基质滴加完全后,继续搅拌1h,使水油两相充分乳化,缓慢滴加交联剂,继续搅拌2h,使交联剂与壳聚糖充分交联,静置分层,去除上层液相,收集沉淀物,用石油醚和无水乙醇分别抽滤洗涤直至滤液澄清透明,此即为载硒壳聚糖微球半成品;滴加丙酮,使载硒壳聚糖微球相互分散,于45℃烘箱中烘干,得载硒壳聚糖微球。
2.根据权利要求1所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(1)中,含硒壳聚糖溶液中壳聚糖质量浓度为0.5%-3%。
3.根据权利要求2所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(1)中,含硒壳聚糖溶液中壳聚糖质量浓度为1%-2%。
4.根据权利要求1所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(1)中,硒醋酸溶液中Na2SeO3的质量浓度为0.2%-1.6%。
5.根据权利要求4所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(1)中,硒醋酸溶液中Na2SeO3的质量浓度为0.4%-0.8%。
6.根据权利要求1所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(3)中,反应温度为35℃-65℃。
7.根据权利要求6所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(3)中,反应温度为45℃-55℃。
8.根据权利要求1所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,步骤(3)中,交联剂用量为2.5%-15%。
9.根据权利要求1所述的可控缓释硒负离子的载硒壳聚糖微球的制备方法,其特征在于,交联剂采用质量分数为12.5%的戊二醛溶液。
10.根据权利要求1-9任一所述的制备方法制得载硒壳聚糖微球。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610176687.3A CN105832675B (zh) | 2016-03-24 | 2016-03-24 | 一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610176687.3A CN105832675B (zh) | 2016-03-24 | 2016-03-24 | 一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105832675A CN105832675A (zh) | 2016-08-10 |
CN105832675B true CN105832675B (zh) | 2018-10-26 |
Family
ID=56583463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610176687.3A Expired - Fee Related CN105832675B (zh) | 2016-03-24 | 2016-03-24 | 一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105832675B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109603786B (zh) * | 2018-12-26 | 2022-03-22 | 东北林业大学 | 基于壳聚糖的单宁微球缓释型甲醛捕捉剂及其制备方法 |
CN110839867A (zh) * | 2019-11-25 | 2020-02-28 | 武汉绿时代创新科技有限公司 | 一种富含硒元素的多品种食用竹盐及其制备方法 |
CN112250511B (zh) * | 2020-10-20 | 2021-10-15 | 南开大学 | 一种新型复合型缓释氧化微球及其制备方法 |
CN114080959A (zh) * | 2021-10-21 | 2022-02-25 | 舒城县农业科学研究所 | 一种有机富硒水稻栽培方法 |
CN114380950B (zh) * | 2022-03-04 | 2022-12-13 | 中国农业大学 | 有机硼交联富硒高吸水性树脂及其制备方法 |
US20240285541A1 (en) * | 2023-02-24 | 2024-08-29 | Glanbia Nutritionals, Inc. | Shelf stable organic nucleotide compositions and methods of manufacturing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594236A (zh) * | 2004-07-06 | 2005-03-16 | 湖南大学 | 果蔬类纳米硒营养调节剂及其制备方法 |
CN101474157A (zh) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | 一种积雪草酸可注射缓释微球及其制备方法 |
-
2016
- 2016-03-24 CN CN201610176687.3A patent/CN105832675B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594236A (zh) * | 2004-07-06 | 2005-03-16 | 湖南大学 | 果蔬类纳米硒营养调节剂及其制备方法 |
CN101474157A (zh) * | 2009-01-19 | 2009-07-08 | 浙江省医学科学院 | 一种积雪草酸可注射缓释微球及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105832675A (zh) | 2016-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105832675B (zh) | 一种可控缓释硒负离子的载硒壳聚糖微球及其制备方法 | |
Veiseh et al. | Size-and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates | |
Yu et al. | Alginate core-shell beads for simplified three-dimensional tumor spheroid culture and drug screening | |
Vinceković et al. | Kinetics and mechanisms of chemical and biological agents release from biopolymeric microcapsules | |
CN102219938A (zh) | 一种疏水改性海藻酸钠的制备方法 | |
Wang et al. | Electrosprayed soft capsules of millimeter size for specifically delivering fish oil/nutrients to the stomach and intestines | |
CN102688195A (zh) | 一种具有pH敏感性的包载盐酸阿霉素的壳聚糖羧甲基壳聚糖纳米缓释微粒的制备方法 | |
CN107281494B (zh) | 一种氧化石墨烯-鱼精蛋白/海藻酸钠复合物的制备方法及应用 | |
Yang et al. | pH-sensitive chitosan–sodium phytate core–shell hollow beads and nanocapsules for the encapsulation of active ingredients | |
CN105085939A (zh) | 三维结构且具有电刺激和pH响应的聚吡咯/海藻酸盐凝胶的制备及双重控制药物释放 | |
CN101732259B (zh) | 壳聚糖微米粒及其制备方法和应用 | |
Keshtiara et al. | Simultaneous immunomodulation and tissue protection on the rheumatoid arthritis models using a Tragacanth Frankincense-based core–Shell Nanostructure | |
Zheng et al. | Celastrol-encapsulated microspheres prepared by microfluidic electrospray for alleviating inflammatory pain | |
CN102727522B (zh) | 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂 | |
CN1935242A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN102010512B (zh) | 水溶性壳聚糖微粒的制备方法和应用 | |
CN103211786A (zh) | 胆碱非诺贝特膜控肠溶缓释微丸胶囊 | |
CN102058530A (zh) | 一种灵芝多糖口服纳米乳剂及其制备方法 | |
Mazumder et al. | Formulation, development and in-vitro release effects of ethyl cellulose coated pectin microspheres for colon targeting | |
CN104127386A (zh) | 一种大叶茜草素/壳聚糖纳米微球及其制备方法和应用 | |
UA122198C2 (uk) | Екстракт danshen, склад на його основі у формі мікропелет, склад у формі капсули з мікропелетами, одержаний з нього, способи його одержання та застосування | |
Xin et al. | Rational design of monodisperse mesoporous silica nanoparticles for phytase immobilization | |
Osial et al. | Nanohydroxyapatite Loaded with 5-Fluorouracil and Calendula officinalis L. Plant Extract Rich in Myo-Inositols for Treatment of Ovarian Cancer Cells | |
Shalaka et al. | Vitamin E loaded pectin alginate microspheres for cosmetic application | |
Coutinho et al. | An automated two-phase system for hydrogel microbead production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181026 |